Oppenheimer reiterates Amgen stock rating on cancer drug data
Oppenheimer reiterated an Outperform rating and $480 price target for Amgen (AMGN) after positive Phase 3 trial results for its cancer drug Imdelltra, showing a 58% reduction in mortality risk. The stock is near its 52-week high, up 55% over the past year. Analysts expect strong revenue and earnings growth, with varying price targets.
How this was made
The 30-second read
Why it matters
The data is expected to boost Amgen's revenue outlook and may trigger a re‑rating by other analysts.
Market read
New pivotal trial data for a major oncology drug, likely to move Amgen's stock and influence the biotech sector.
What to watch
Potential competition from other SCLC therapies and the need for reimbursement approvals could temper the rally.
Background
Amgen announced positive Phase 3 data for its BiTE platform therapy Imdelltra in small cell lung cancer, prompting analyst rating upgrades.
Ticker impact
Oppenheimer reiterated an Outperform rating and raised the price target to $480 after positive Phase 3 trial data for Amgen's cancer therapy Imdelltra.
upward pressure as investors price in the new efficacy data and potential market expansion.
Phase 3 data showing a 58% mortality reduction is material for a large biotech; analysts have already raised targets, indicating strong market reaction.
Market effects
Strengthens the outlook for the oncology biotech sector, potentially lifting peers with similar pipelines.
Positive for US biotech equities and may boost Nasdaq biotech indices.
Adds confidence to global investors tracking cancer therapeutics and may influence cross‑border biotech collaborations.
Counterpoint
If regulatory approval timelines extend or pricing pressures emerge, the upside could be limited.
Key entities
- companyAmgen Inc.
US‑listed biotech developing Imdelltra.
- analyst_firmOppenheimer
Raised price target to $480 and reiterated Outperform rating.
